FIELD: biotechnology.
SUBSTANCE: invention relates to methods for determination of whether a patient with an oncological disease, having tumor positive by a tumor antigen, responds to treatment, using an antibody against a tumor antigen, and methods for determination of whether a patient with an oncological disease, having tumor positive by a tumor antigen, will have a progression-free survival period. In this case, the tumor antigen is CLDN18.2 protein. A method for the treatment of a patient with an oncological disease, having tumor positive by an antigen, is also presented.
EFFECT: invention allows for its effective use for prediction of the efficiency of treatment of malignant neoplasms and prediction of clinical outcomes for patients with oncological diseases.
16 cl, 14 dwg, 16 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| CD40L ANTIBODIES AND METHODS OF TREATING CD40L RELATED DISEASES AND DISORDERS | 2016 |
|
RU2727646C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| COMPOSITIONS OF IMMUNOGENIC/THERAPEUTIC GLYCOCONJUGATES AND USE THEREOF | 2015 |
|
RU2720295C2 |
